What is Nektar Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nektar Therapeutics's interest expense for the
three
months ended in Dec. 2023 was $ -6.87 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.33 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nektar Therapeutics's Operating Income for the
three
months ended in Dec. 2023 was $ -30.66 Mil. Nektar Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $ -6.87 Mil.
Nektar Therapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Nektar Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics (NAS:NKTR) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Nektar Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $-6.87 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-30.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $98.52 Mil.
Nektar Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Nektar Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Executives
| Howard W Robin |
director, officer: President & CEO |
|
| Jonathan Zalevsky |
officer: Chief R&D Officer |
455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
| Mark Andrew Wilson |
officer: SVP & General Counsel |
1613 RAY DRIVE, BURLINGAME CA 94010 |
| Myriam Curet |
director |
1020 KIFER ROAD, SUNNYVALE CA 94086 |
| Jeffrey Robert Ajer |
director |
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
| Sandra A. Gardiner |
officer: Chief Financial Officer |
CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Jillian B. Thomsen |
officer: VP & Chief Accounting Officer |
C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
| Robert Chess |
director, officer: Executive Chairman |
|
| Karin Eastham |
director |
C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
| Gil M Labrucherie |
officer: SVP, COO & CFO |
150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
| John Northcott |
officer: SVP & Chief Commercial Officer |
455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
| Diana Brainard |
director |
C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
| R Scott Greer |
director |
6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253 |
| Lutz Lingnau |
director |
15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945 |
| Stephen K Doberstein |
officer: Chief Scientific Officer |
129 ELSIE STREET, SAN FRANCISCO CA 94110 |
Nektar Therapeutics (Nektar Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 